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Abstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. 
However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its 
utility for basic research and therapeutic applications that employ the highly versatile adeno-
associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologs and 
show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies 
similar to those of SpCas9, while being >1kb shorter. We packaged SaCas9 and its sgRNA 
expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in 
the mouse liver. Within one week of injection, we observed >40% gene modification, 
accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further 
demonstrate the power of using BLESS to assess the genome-wide targeting specificity of SaCas9 
and SpCas9, and show that SaCas9 can mediate genome editing in vivo with high specificity.
Introduction
Cas9, an RNA-guided endonuclease derived from the Type II CRISPR-Cas bacterial 
adaptive immune system1–7, has been harnessed for genome editing8,9 and holds tremendous 
promise for biomedical research. Genome editing of somatic tissue in post-natal animals, 
however, has been limited in part by the challenge of delivering Cas9 in vivo. For this 
purpose, adeno-associated virus (AAV) vectors are attractive vehicles10 because of their low 
immunogenic potential, reduced oncogenic risk from host-genome integration11, and broad-
range of serotype specificity12–15. Nevertheless, the restrictive cargo size (~4.5kb) of AAV 
presents an obstacle for packaging the commonly used Streptococcus pyogenes Cas9 
(SpCas9, ~4.2kb) and its sgRNA in a single vector; although technically feasible16,17, this 
approach leaves little room for customized expression and control elements.
In search of smaller Cas9 enzymes for efficient in vivo delivery by AAV, we have 
previously described a short Cas9 from the CRISPR1 locus of Streptococcus thermophilus 
LMD-9 (St1Cas9, ~3.3kb)8 as well as a rationally-designed truncated form of SpCas918 for 
genome editing in human cells. However, both systems have important practical drawbacks: 
the former requires a complex Protospacer-Associated Motif (PAM) sequence 
(NNAGAAW)3, which restricts the range of accessible targets, whereas the latter exhibits 
reduced activity. Given the substantial diversity of CRISPR-Cas systems present in 
sequenced microbial genomes19, we therefore sought to interrogate and discover additional 
Cas9 enzymes that are small, efficient, and broadly targeting.
In vitro cleavage by small Cas9s
Type II CRISPR-Cas systems require only two main components for eukaryotic genome 
editing: a Cas9 enzyme, and a chimeric single guide RNA (sgRNA)6 derived from the 
CRISPR RNA (crRNA) and the noncoding trans-activating crRNA (tracrRNA)4,20. Analysis 
of over 600 Cas9 orthologs shows that these enzymes are clustered into two length groups 
with characteristic protein sizes of approximately 1350aa and 1000aa residues, 
respectively19,21 (Extended Data Fig. 1a), with shorter Cas9s having significantly truncated 
REC domains (Fig. 1a). From these shorter Cas9s, which belong to Type IIA and IIC 
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subtypes, we selected six candidates for profiling (Fig. 1a and Extended Data Fig. 1b). To 
determine the cognate crRNA and tracrRNA for each Cas9, we computationally identified 
regularly interspaced repeat sequences (direct repeats) within a 2-kb window flanking the 
CRISPR locus. We then predicted the tracrRNA by detecting sequences with strong 
complementarity to the direct repeat sequence (an anti-repeat region), at least two predicted 
stem-loop structures, and a Rho-independent transcriptional termination signal up to 150-nt 
downstream of the anti-repeat region. Although a truncated tracrRNA can support robust 
DNA cleavage in vitro6, previous reports show that the secondary structures of the 
tracrRNA are important for Cas9 activity in mammalian cells8,9,18,22. Therefore, we 
designed sgRNA scaffolds for each ortholog by fusing the 3′ end of a truncated direct repeat 
with the 5′ end of the corresponding tracrRNA, including the full-length tail, via a 4-nt 
linker6 (Extended Data Fig. 1b and Supplementary Table 1). To identify the PAM sequence 
for each Cas9, we first constructed a library of plasmid DNA containing a constant 20-bp 
target followed by a degenerate 7-bp sequence (5′-NNNNNNN). We then incubated cell 
lysate from human embryonic kidney 293FT (293FT) cells expressing the Cas9 ortholog 
with its in vitro transcribed sgRNA and the plasmid library. By generating a consensus from 
the 7-bp sequence found on successfully cleaved DNA plasmids (Fig. 1b), we determined 
putative PAMs for each Cas9 (Fig. 1c). We observed that, similar to SpCas9, most Cas9 
orthologs cleaved targets 3-bp upstream of the PAM (Extended Data Fig. 2). To validate 
each putative PAM from the library, we then incubated a DNA template bearing the 
consensus PAM with cell lysate and the corresponding sgRNA. We found that the Cas9 
orthologs, in combination with the sgRNA designs, successfully cleaved the appropriate 
targets (Fig. 1d and Supplementary Table 2).
To test whether each Cas9 ortholog can facilitate genome editing in mammalian cells, we 
co-transfected 293FT cells with individual Cas9s and their respective sgRNAs targeting 
human endogenous loci containing the appropriate PAMs. Of the six Cas9 orthologs tested, 
only the one from Staphylococcus aureus (SaCas9) produced indels with efficiencies 
comparable to those of SpCas9 (Extended Data Fig. 3a, b and Supplementary Table 3), 
suggesting that DNA-cleavage activity in cell-free assays does not necessarily reflect the 
activity in mammalian cells. These observations prompted us to focus on harnessing SaCas9 
and its sgRNA for in vivo applications.
SaCas9 sgRNA design and PAM discovery
Although mature crRNAs in S. pyogenes are processed to contain 20-nt spacers (guides) and 
19- to 22-nt direct repeats4, RNA sequencing of crRNAs from other organisms reveals that 
the spacer and direct repeat sequence lengths can vary4,20,23. We therefore tested sgRNAs 
for SaCas9 with variable guide lengths and repeat:anti-repeat duplexes. We found that 
SaCas9 achieves the highest editing efficiency in mammalian cells with guides between 21- 
to 23-nt long and can accommodate a range of lengths for the direct repeat:anti-repeat region 
(Fig. 2a, b, Extended Data Fig. 4). This notably contrasts with SpCas9, where the natural 20-
nt guide length can be truncated to 17-nt without significantly compromising nuclease 
activity, while increasing specificity24. Additionally, replacing the first base of the guide 
with guanine further improved SaCas9 activity (Extended Data Fig. 3c).
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To fully characterize the SaCas9 PAM and the seed region within its guide sequence25, we 
performed ChIP using catalytically mutant forms of SaCas9 (dSaCas9, D10A and N580A 
mutations, based on homology to SpCas9) or SpCas9 (dSpCas9, D10A and H840A 
mutations) and their corresponding sgRNAs. We targeted two loci in the human EMX1 gene 
with composite NGGRRT PAMs, which allow targeting by both Cas9 variants. A search for 
motifs containing both the guide region and PAM within 50-nt of the ChIP peak summits 
revealed seed sequences of 7–8 nt for dSaCas9 (Fig. 2c). In addition, NNGRRT and NGG 
PAMs were found adjacent to the seed sequences for dSaCas9 and dSpCas9, respectively 
(Extended Data Fig. 5). Although the 6th position of the PAM is predominantly thymine, we 
did observe low levels of degeneracy in both the biochemical and ChIP-based PAM 
discovery assays (Fig. 1c and Extended Data Fig. 5a). We therefore tested the base 
preference for this position and determined that although SaCas9 cleaves genomic targets 
most efficiently with NNGRRT, all NNGRR PAMs can be cleaved and should be 
considered as potential targets, especially in the context of off-target evaluations (Fig. 2d, 
Extended Data Fig. 6, and Supplementary Table 4).
Unbiased profiling of Cas9 specificity
As advances in Cas9 technology promise to enable a broad range of in vivo and therapeutic 
applications, accurate, genome-wide identification of off-target nuclease activity has become 
increasingly important. Although a number of studies have employed sequence similarity-
based off-target search22,26–30 or dCas9-ChIP31,32 to predict off-target sites for Cas9, such 
approaches cannot assess the nuclease activity of Cas9 in a comprehensive and unbiased 
manner. To directly measure the genome-wide cleavage activity of SaCas9 and SpCas9, we 
applied BLESS (direct in situ breaks labeling, enrichment on streptavidin and next-
generation sequencing)33 to capture Cas9-induced DNA double-stranded breaks (DSBs) in 
cells. We transfected 293FT cells with SaCas9 or SpCas9 and the same EMX1 targeting 
guides used in the previous ChIP experiment, or pUC19 as negative controls. After cells are 
fixed, free genomic DNA ends from DSBs are captured using biotinylated adaptors and 
analyzed by deep sequencing (Fig. 3a). To identify candidate Cas9-induced DSB sites 
genome-wide, we established a three-step analysis pipeline following alignment of the 
sequenced BLESS reads to the genome (Extended Data Fig. 7a, Supplementary Discussion). 
First, we applied nearest-neighbor clustering on the aligned reads to identify groups of DSBs 
(DSB clusters) across the genome. Second, we sought to separate potential Cas9-induced 
DSB clusters from background DSB clusters resulting from low frequency biological 
processes and technical artifacts, as well as high frequency telomeric and centromeric DSB 
hotspots33. From the on-target and a small subset of verified off-target sites (predicted by 
sequence similarity using a previously established method22 and sequenced to detect indels), 
we found that reads in Cas9-induced DSB clusters mapped to characteristic, well-defined 
genomic positions compared to the more diffuse alignment pattern at background DSB 
clusters. To distinguish between the two types of DSB clusters, we calculated in each cluster 
the distance between all possible pairs of forward and reverse-oriented reads (corresponding 
to 3′ and 5′ ends of DSBs), and filtered out the background DSB clusters based on the 
distinctive pairwise-distance distribution of these clusters (Extended Data Fig. 7b, c). Third, 
the DSB score for a given locus was calculated by comparing the count of DSBs in the 
experimental and negative control samples using a maximum-likelihood estimate (MLE)22 
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(Supplementary Discussion). This analysis identified the on-target loci for both SaCas9 and 
SpCas9 guides as the top scoring sites, and revealed additional sites with high DSB scores 
(Fig. 3b–d).
Next, we sought to assess whether DSB scores correlated with indel formation. We used 
targeted deep sequencing to detect indel formation on the ~30 top-ranking off-target sites 
identified by BLESS for each Cas9 and sgRNA combination. We found that only those sites 
that contained PAM and homology to the guide sequence exhibited indels (Extended Data 
Fig. 8). We observed a strong linear correlation between DSB scores and indel levels for 
each Cas9 and sgRNA pairing (r2 = 0.948 and 0.989 for the two EMX1 targets with SaCas9 
and r2 = 0.941 and 0.753 for those with SpCas9) (Fig. 3c, Extended Fig. 9b–d). Furthermore, 
BLESS identified additional off-target sites not previously predicted by sequence similarity 
to target or ChIP (Extended Data Fig. 7 and 9, Supplementary Tables 5 and 6). These new 
off-target sites include not only those containing Watson-Crick base-pairing mismatches to 
the guide, but also the recently reported insertion and deletion mismatches in the 
guide:target heteroduplex (Fig. 3d)29,30. Together, these results highlight the need for more 
precise understanding of rules governing Cas9 nuclease activity, a requisite step towards 
improving the predictive power of computational guide design programs.
In vivo genome editing using SaCas9
Following in vitro characterization, we incorporated SaCas9 and its sgRNA into an AAV 
vector to test its efficacy and specificity in vivo. The small size of SaCas9 enables packaging 
of both a U6-driven sgRNA and a CMV- or TBG-driven SaCas9 expression cassette into a 
single AAV vector within the 4.5kb packaging limit. Using hepatocyte-tropic AAV serotype 
8, we targeted the mouse apolipoprotein (Apob) gene (Extended Data Fig. 10a). One week 
after intravenous administration of virus into C57BL/6 mice, we observed ~5% indel 
formation in liver tissue; after four weeks, the liver tissue showed characteristic hepatic lipid 
accumulation from Apob knockdown following histology analysis using oil red 
staining34–37 (Extended Data Fig. 10b, c).
We next targeted proprotein convertase subtilisin/kexin type 9 (Pcsk9), a therapeutically 
relevant gene involved in cholesterol homeostasis38. Inhibitors of the human convertase 
PCSK9 have emerged as a promising new class of cardioprotective drugs after human 
genetic studies revealed that loss of PCSK9 is associated with a reduced risk of 
cardiovascular disease and lower levels of LDL cholesterol39–41. We designed two Pcsk9-
targeting sgRNAs and validated their activity in vitro. Each sgRNA was packaged into 
AAV-SaCas9 and injected into mice (2E11 total genome copies) (Fig. 4a). One week after 
administration, we observed greater than 40% indel formation at either locus in whole liver 
tissue, with similar levels two and four weeks post-injection (Fig. 4b). To determine the 
effect of Pcsk9-targeting AAV-SaCas9 dosage on serum Pcsk9 and total cholesterol levels, 
we administered a range of AAV titers from 0.5E11 to 4E11 total genome copies. With all 
titers, we observed a ~95% decrease in serum Pcsk9 and a ~40% decrease in total 
cholesterol one week after administration, both of which were sustained throughout the 
course of four weeks (Fig. 4c, d).
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Given the importance of targeting specificity in a therapeutic context, we next considered 
SaCas9 off-target modifications in vivo. To identify candidate off-target cleavage sites for 
the two Pcsk9-targeting guides, we transiently transfected an AAV-CMV::SaCas9 vector 
into mouse Neuroblastoma-2a (N2a) cells and applied BLESS to detect Cas9-induced DSBs 
in the genome. For both guides, we found very low levels of DSB signal across the genome 
except at the on-target locus (Fig. 4e). Targeted deep sequencing of the candidate off-target 
sites identified by BLESS in N2a cells did not reveal appreciable levels of indels in either 
N2a cells or liver tissue (4 weeks post injection of 2E11 total genome copies) (Fig. 4e, f and 
Supplementary Table 8). We additionally sequenced off-target sites predicted by target 
sequence similarity, and likewise did not detect indel formations (Supplementary Table 9).
Finally, we examined the titer-matched Pcsk9-targeting and TBG-GFP cohorts as well as 
naïve animals for signs of toxicity or acute immune response. At 1 week post-injection, 
necropsy and gross examination of liver tissue of the cohorts revealed no abnormalities; 
further histological examination of the liver by hematoxylin and eosin (H&E) staining 
showed no signs of inflammation, such as aggregates of lymphocytes or macrophages (Fig. 
5a). Throughout the time course of the experiment, there were no elevated levels of serum 
ALT, albumin, and total bilirubin in any of the cohorts. We observed a slight trend in AST 
increase across all cohorts at four weeks, including the un-injected animals. The elevated 
levels did not exceed the upper limit of normal and is not indicative of hepatocellular injury 
(Fig. 5b). However, a larger cohort study should be conducted to further evaluate the effects 
of in vivo toxicity.
Discussion
Here, we develop a small and efficient Cas9 from S. aureus for in vivo genome editing17. 
The results of these experiments highlight the power of using comparative genomic 
analysis19,42 in expanding the CRISPR-Cas toolbox. Identification of new Cas9 
orthologs19,42, in addition to structure-guided engineering, could yield a repertoire of Cas9 
variants with expanded capabilities and mimized molecular weight, for nucleic acid 
manipulation to further advance genome and epigenome engineering.
The AAV-SaCas9 system is able to mediate efficient and rapid editing of Pcsk9 in the 
mouse liver, resulting in reductions of serum Pcsk9 and total cholesterol levels. To assess 
the specificity of SaCas9, we used an unbiased DSB detection method, BLESS, to identify a 
list of candidate off-target cleavage sites in mouse cells. We examined these sites in liver 
tissue transduced by AAV-SaCas9 and did not observe any indel formation within the 
detection limits of targeted deep sequencing. However, the off-target sites identified in vitro 
might differ from those in vivo, which need to be further evaluated by the in vivo 
applications of BLESS or other unbiased techniques such as those published during the 
revision of this work43,44. Finally, we did not observe any overt signs of acute toxicity at 
one to four weeks post virus administration. Although further studies are needed to further 
improve the SaCas9 system for in vivo genome editing, such as assessing the long-term 
impact of Cas9 and sgRNA expression, these findings suggest that in vivo genome editing 
using SaCas9 has the potential to be highly efficient, specific, and well-tolerated.
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Methods
In vitro transcription and cleavage assay
Cas9 orthologs were human codon-optimized and synthesized by GenScript, and transfected 
into 293FT cells as described below. Whole cell lysates from 293FT cells were prepared 
with lysis buffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl2, 1 mM DTT, 5% glycerol, 
0.1% Triton X-100) supplemented with Protease Inhibitor Cocktail (Roche). T7-driven 
sgRNA was transcribed in vitro using custom oligos (Supplementary Information) and 
HiScribe T7 In vitro Transcription Kit (NEB), following the manufacturer’s recommended 
protocol. The in vitro cleavage assay was carried out as follows: for a 20 μl cleavage 
reaction, 10 μl of cell lysate was incubated with 2 μl cleavage buffer (100 mM HEPES, 500 
mM KCl, 25 mM MgCl2, 5 mM DTT, 25% glycerol), 1 μg in vitro transcribed RNA and 
200 ng EcoRI-linearized pUC19 plasmid DNA or 200 ng purified PCR amplicons from 
mammalian genomic DNA containing target sequence. After 30 min incubation, cleavage 
reactions were purified using QiaQuick Spin Columns and treated with RNase A at final 
concentration of 80 ng/μl for 30 min and analyzed on a 1% Agarose E-Gel (Life 
Technologies).
In vitro PAM screen
Rho-independent transcriptional termination was predicted using the ARNold terminator 
search tool47,48. For the PAM library, a degenerate 7-bp sequence was cloned into a pUC19 
vector. For each ortholog, the in vitro cleavage assay was carried out as above with 1 μg T7-
transcribed sgRNA and 400 ng pUC19 with degenerate PAM. Cleaved plasmids were 
linearized by NheI, gel extracted, and ligated with Illumina sequencing adaptors. Barcoded 
and purified DNA libraries were quantified by Quant-iT PicoGreen dsDNA Assay Kit or 
Qubit 2.0 Fluorometer (Life Technologies) and pooled in an equimolar ratio for sequencing 
using the Illumina MiSeq Personal Sequencer (Life Technologies). MiSeq reads were 
filtered by requiring an average Phred quality (Q score) of at least 23, as well as perfect 
sequence matches to barcodes. For reads corresponding to each ortholog, the degenerate 
region was extracted. All extracted regions were then grouped and analyzed with 
Weblogo45.
Cell culture and transfection
Human embryonic kidney 293FT (Life Technologies), Neuro-2a (N2a), and Hepa1-6 
(ATCC) cell lines were maintained in Dulbecco’s modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS (HyClone), 2 mM GlutaMAX (Life Technologies), 100 U/ml 
penicillin, and 100 μg/ml streptomycin at 37 °C with 5% CO2 incubation.
Cells were seeded into 24-well plates (Corning) one day prior to transfection at a density of 
240,000 cells per well, and transfected at 70–80% confluency using Lipofectamine 2000 
(Life Technologies) following the manufacturer’s recommended protocol. For each well of a 
24-well plate, a total of 500 ng DNA was used. For ChIP and BLESS, a total of 4.5 million 
cells are seeded the day before transfection into a 100mm plate, and a total of 20 ug DNA 
was used.
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DNA isolation from cells and tissue
Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre). 
Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65 °C for 
15 min, 68 °C for 15 min, and 98 °C for 10 min8. Genomic liver DNA was extracted from 
bulk tissue fragments using a microtube bead mill homogenizer (Beadbug, Denville 
Scientific) by homogenizing approximately 30–50 mg of tissue in 600 μL of DPBS (Gibco). 
The homogenate was then centrifuged at 2000 to 3000×g for 5 minutes at 4°C and the pellet 
was resuspended in 300–600 μL QuickExtract DNA Extraction Solution (Epicentre) and 
incubated as above.
Indel analysis and guide:target basepairing mismatch search
Indel analyses by SURVEYOR assay and targeted deep sequencing were carried out and 
analyzed as previously described8,22. The methods for identification of potential off-target 
sites for SpCas9 based on Watson-Crick base-pairing mismatch between guide RNA and 
target DNA has been previously described22, and adapted for SaCas9 by considering 
NNGRR for possible off-target PAMs.
Chromatin immunoprecipitation and analysis
Cells are passaged at 24 hours post-transfection into a 150mm dish, and fixed for ChIP 
processing at 48 hours post-transfection. For each condition, 10 million cells are used for 
ChIP input, following experimental protocols and analyses as previously described31 with 
the following modifications: instead of pairwise peak-calling, ChIP peaks were only 
required to be enriched over both ‘empty’ controls (dSpCas9 only, dSaCas9 only) as well as 
the other Cas9/other sgRNA sample (e.g., SpCas9/EMX-sg2 peaks must be enriched over 
SaCas9/EMX-sg1 peaks in addition to the empty controls). This was done to avoid filtering 
out of real peaks present in two related samples as much as possible.
To identify off-targets ranked by motif or sequence similarity to guide, motif scores for 
ChIP peaks were calculated as follows: For a given ChIP peak, the 100-nt interval around 
the peak summit, the target sequence, and a given sgRNA guide region L, the query, an 
alignment score is calculated for every subsequence of length L in the target. The 
subsequence with the highest score is reported as the best match to the query. For each 
subsequence alignment, the score calculation begins at the 5′ end of the query. For each 
position in the alignment, 1 is added or subtracted for match or mismatch between the query 
and target, respectively. If the score becomes negative, it is set to 0 and the calculation 
continued for the remainder of the alignment. The score at the 3′ end of the query is reported 
as the final score for the alignment. MACS scores = −10log(p-value relative to the empty 
control) are determined as previously described49. For unbiased determination of PAM from 
ChIP peaks, the peaks were analyzed for the best match by motif score to the guide region 
only within 50-nt of the peak summit; the alignment was extended for 10-nt at the 3′ end and 
visualized using Weblogo45.
To calculate the motif score threshold at which FDR < 0.1 for each sample, 100-nt 
sequences centered around peak summits were shuffled while preserving dinucleotide 
frequency. The best match by motif score to the guide+PAM (NGG for SpCas9, NNGRRT 
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for SaCas9) in these shuffled sequences was then found. The score threshold for FDR < 0.1 
was defined as the score such that less than 10% of shuffled peaks had a motif score above 
that score threshold.
BLESS for DSB detection
Cells are harvested at 24 hours post-transfection, then processed as previously described33 
with the following alterations: a total of 10 million cells are fixed for nuclei isolation and 
permeabilization, and treated with Proteinase K for 4 min at 37°C before inactivation with 
PMSF. All deproteinized nuclei are used for DSB labeling with 100 mM of annealed 
proximal linkers overnight. After Proteinase K digestion of labeled nuclei, chromatin are 
mechanically sheared with a 26G needle before sonication (BioRuptor, 20 min on High, 
50% duty cycle). 20 ug of sheared chromatin are captured on streptavidin beads, washed, 
and ligated to 200 mM of distal linker. Linker hairpins are then cleaved off with I-SceI 
digestion for 1 hour at 37°C, and products PCR-enriched for 18 cycles before proceeding to 
library preparation with TruSeq Nano LT Kit (Illumina). For the negative control, cells 
mock transfected with Lipofectamine 2000 and pUC19 DNA were parallel processed 
through the assay.
BLESS Analysis
Fastq files were demultiplexed, and 30-bp genomic sequences were separated from the 
BLESS ligation handles for alignment. Bowtie was used to map the genomic sequences to 
hg19 or mm9, allowing for a maximum of 2 mismatches. Following alignment, reads from 
all bio-replicates for an individual sample were first pooled, and then nearest neighbor 
clustering was performed with a 30-bp moving window to identify regions of enrichment 
across the genome. Within each cluster, the pairwise distance was calculated between all 
forward and reverse read strand mappings (Extended Data Figure 7b, c). Pairwise distance 
distributions were used to filter out wide and poorly-defined DSB clusters from the well-
defined DSB clusters characteristically found at Cas9-induced cleavage sites (see 
Supplementary Information). Finally, we adjusted the count of predicted Cas9-induced 
DSBs at a given locus by using a binomial model to calculate the maximum-likelihood 
estimate (MLE) of peak enrichment in the Cas9-sgRNA treated sgRNAs given BLESS 
measurements from an untreated negative control. After the MLE calculation, a list of loci 
ranked by their DSB scores could be obtained and plotted (Figure 3b, Extended Data Figure 
8). Additional descriptions can be found in Supplementary Information.
The top-ranking ~30 sites from the list of Cas9 induced DSB clusters were sequenced for 
indel formation (Extended Data Figure 8; validated targets in Figure 3d). Within these loci, 
PAMs and regions of target homology were identified by first searching all PAM sites 
within a ±50 bp window around the DSB cluster, then selecting the adjacent sequence with 
fewest mismatches to the target sequence.
Code Availability
BLESS analysis code is available upon request.
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Virus Production and Titration
For in-house viral production, 293FT cells (Life Technologies) were maintained as 
described above in 150mm plates. For each transfection, 8 ug of pAAV8 serotype packaging 
plasmid, 10 ug of pDF6 helper plasmid, and 6 ug of AAV2 plasmid carrying the construct of 
interest were added to 1mL of serum-free DMEM. 125 μL of PEI “Max” solution (1mg/mL, 
pH = 7.1) was then added to the mixture and incubated at room temperature for 5 to 10 
seconds. After incubation, the mixture was added to 20 mL of warm maintenance media and 
applied to each dish to replace the old growth media. Cells were harvested between 48h and 
72h post transfection by scraping and pelleting by centrifugation. The AAV2/8 (AAV2 ITR 
vectors pseudo-typed with AAV8 capsid) viral particles were then purified from the pellet 
according to a previously published protocol50.
High titer and purity viruses were also produced by vector core facilities at Children’s 
Hospital Boston and Massachusetts Eye and Ear Infirmary (MEEI). These AAV vectors 
were then titered by real-time qPCR using a customized TaqMan probe against the 
transgene, and all viral preparations were titer-matched across different batches and 
production facilities prior to experiments. The purity of AAV vector was further verified by 
SDS-PAGE.
Animal Injection and Processing
All mice cohorts were maintained at animal facility with standard diet and housing 
following IRB-approved protocols. AAV vector was delivered to 5–6 week old male 
C57/BL6 mice intravenously via lateral tail vein injection. All dosages of AAV were 
adjusted to 100 μL or 200 μL with sterile phosphate buffered saline (PBS), pH 7.4 (Gibco) 
before the injection. Animals were not immunosuppressed or otherwise handled differently 
prior to injection or during the course of the experiment except the pre-bleed fasting as noted 
below. The animals were randomized to the different experimental conditions, with the 
investigator not blinded to the assignments.
To track the serum levels of Pcsk9 and total cholesterol, animals were fasted overnight for 
12 hours prior to blood collection by saphenous vein bleeds (no more than 100 μL or 10% of 
total blood volume per week). Multiple bleeds were made prior to tail vein delivery of AAV 
vector or control to collect pre-injection samples and to habituate the animals to handling 
during the procedure. After the blood was allowed to clot at room temperature, the serum 
was separated by centrifugation and stored at −20°C for subsequent analysis. For terminal 
procedures to collect liver tissue and larger serum volumes for chemistry panels, mice were 
euthanized by carbon dioxide inhalation. Subsequently, blood was collected via cardiac 
puncture. Transcardial perfusion with 30 mL PBS removed the remaining blood, after which 
liver samples were collected. The median lobe of liver was removed and fixed in 10% 
neutral buffered formalin for histological analysis, while the remaining lobes were sliced in 
small blocks of size less than 1×1×3mm3 and frozen for subsequent DNA or protein 
extraction.
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Histology and serum analysis
Following tissue harvesting as described above, flash-frozen mouse liver samples were 
embedded in O.C.T. compound (Tissue Tek, Cat # 4583), snap-frozen, and stored at −80°C 
prior to processing. Frozen tissues were cryosectioned at 4-micron in thickness and stained 
with Oil Red O following manufacturer’s recommended protocol. Liver histology was 
assessed by H&E staining sections of 10% neutral buffer formalin fixed liver sections.
Serum levels of Pcsk9 were determined by ELISA using the Mouse Proprotein Convertase 
9/PCSK9 Quantikine ELISA Kit (MPC-900, R&D Systems), following the manufacturer’s 
instructions. Total cholesterol levels were measured using the Infinity Cholesterol Reagent 
(Thermo Fisher) per the manufacturer’s instructions. Serum ALT, AST, albumin and total 
bilirubin were measured by an Olympus AU5400 (IDEXX Memphis, TN).
Extended Data
Extended Data Figure 1. Selection of Type II CRISPR-Cas loci from eight bacterial species
a, Distribution of lengths for Cas9 >600 Cas9 orthologs19. b, Schematic of Type II CRISPR-
Cas loci and sgRNA from eight bacterial species. Spacer or “guide” sequences are shown in 
blue, followed by direct repeat (gray). Predicted tracrRNAs are shown in red, and folded 
based on the Constraint Generation RNA folding model46.
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Extended Data Figure 2. Cas9 ortholog cleavage pattern in vitro
Stacked bar graph indicates the fraction of targets cleaved at 2, 3, 4, or 5-bp upstream of 
PAM for each Cas9 ortholog; most Cas9s cleave stereotypically at 3-bp upstream of PAM 
(red triangle).
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Extended Data Figure 3. Test of Cas9 ortholog activity in 293FT cells
a, SURVEYOR assays showing indel formation at human endogenous loci from co-
transfection of Cas9 orthologs and sgRNA. PAM sequences for individual targets are shown 
above each lane, with the consensus region for each PAM highlighted in red. Red triangles 
indicate cleaved fragments. b, SaCas9 generates indels efficiently for a multiple targets. c, 
Box-whisker plot of indel formation as a function of SaCas9 guide length L, with unaltered 
guides (perfect match of L nucleotides, gray bars) or replacement of the 5′-most base of 
guide with guanine (G + L −1 nucleotides, blue bars) (n = 8 guides).
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Extended Data Figure 4. Optimization of SaCas9 sgRNA scaffold in mammalian cells
a, Schematic of the Staphylococcus aureus subspecies aureus CRISPR locus. b, Schematic 
of SaCas9 sgRNA with 21-nt guide, crRNA repeat (gray), tetraloop (black) and tracrRNA 
(red). The number of crRNA repeat to tracrRNA anti-repeat base-pairing is indicated above 
the gray boxes. SaCas9 cleaves targets with varying repeat:anti-repeat lengths in c, HEK 
293FT and d, Hepa1-6 cell lines. (n=3, error bars show S.E.M.)
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Extended Data Figure 5. Genome-wide binding by Cas9-chromatin immunoprecipitation 
(dCas9-ChIP)
a, Unbiased identification of PAM motif for dSaCas9 and dSpCas9. Peaks were analyzed for 
the best match by motif score to the guide region only within 50-nt of the peak summit. The 
alignment extended for 10-nt at the 3′ end and visualized using Weblogo. Numbers in 
parentheses indicate the number of called peaks. b, Histograms show the distribution of the 
peak summit relative to motif for dSaCas9 and dSpCas9. Position 1 on x-axis indicates the 
first base of PAM.
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Extended Data Figure 6. Indel measurements at candidate off-target sites based on ChIP
Indels at top off-target sites predicted by dCas9-ChIP for each Cas9 and sgRNA pair, based 
on ChIP peaks ranked by sequence similarity of the genomic loci to the guide motif 
(heatmap in purple), or p-value of ChIP enrichment over control (heatmap in red). Lines 
connect the common targets (EMX1) and off-targets between the two Cas9s.
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Extended Data Figure 7. Analysis pipeline of sequencing data from BLESS
a, Overview of the data analysis pipeline starting from the raw sequencing reads. 
Representative sequencing read mappings and corresponding histograms of the pairwise 
distances between all the forward orientation (red) reads and reverse orientation (blue) reads, 
displayed for representative b, DSB hotspots and poorly-defined DSB sites and c, Cas9 
induced DSBs with detectable indels. Fraction of pairwise distances between reads 
overlapping by no more than 6bp (dashed vertical line) are indicated over histogram plots.
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Extended Data Figure 8. Indel measurements at off-target sites based on DSB scores
List of top off-target sites ranked by DSB scores for each Cas9 and sgRNA pair. Indel levels 
are determined by targeted deep sequencing. Blue triangles indicate positions of peak 
BLESS signal, and where present, PAMs and targets with sequence homology to the guide 
are highlighted. Lines connect the common on-targets (EMX1) and off-targets between the 
two Cas9s. N.D. not determined.
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Extended Data Figure 9. Indel measurements of top candidate off-target sites based on sequence 
similarity score
Off-targets are predicted based on sequence similarity to on-target, accounting for number 
and position of Watson-Crick base-pairing mismatches as previously described22. NNGRR 
and NRG are used as potential PAMs for SaCas9 and SpCas9, respectively. Lines connect 
the common targets (EMX1) and off-targets between the two Cas9s. Correlation plots 
between indel percentages and b, prediction based on sequence similarity, c, ChIP peaks 
ranked by motif similarity, or d, DSB scores for top ranking off-target loci. Trendlines, r2, 
and p-values are calculated using ordinary least squares.
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Extended Data Figure 10. SaCas9 targeting Apob locus in the mouse liver
a, Schematics illustrating the mouse Apob gene locus and the positions of the three guides 
tested. b, Experimental time course and c, SURVEYOR assay showing indel formation at 
target loci after intravenous injection of AAV2/8 carrying thyroxine-binding globulin (TBG) 
promoter-driven SaCas9 and U6-driven guide at 2E11 total genome copies (n = 1 animal 
each). d, Oil-red staining of liver tissue from AAV- or saline-injected animals. Male 
C56BL/6 mice were injected at 8 weeks of age and analyzed 4 weeks post injection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Biochemical screen for small Cas9 orthologs
a, Phylogenetic tree of selected Cas9 orthologs. Subfamily and sizes (amino acids) are 
indicated, with nuclease domains highlighted in colored boxes, and conserved sequences in 
black. b, Schematic illustration of the in vitro cleavage-based method used to identify the 
first seven positions (5′-NNNNNNN) of protospacer adjacent motifs (PAMs). c, Consensus 
PAMs for eight Cas9 orthologs from sequencing of cleaved fragments. Error bars are 
Bayesian 95% confidence interval45. d, Cleavage using different orthologs and sgRNAs 
targeting loci bearing the putative PAMs (consensus shown in red). Red triangles indicate 
cleavage fragments.
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Figure 2. Characterization of Staphylococcus aureus Cas9 (SaCas9) in 293FT cells
a, SaCas9 sgRNA scaffold (red) and guide (blue) base-pairing at target locus (black) 
immediately 5′ of PAM. b, Box-whisker plot showing indels vary depending on the length 
of the guide sequence (n=4). c, dSaCas9-ChIP reveals peaks associated with seed + PAM. 
Text to the right indicates the total number of peaks and percentage containing significant 
(FDR < 0.1) match to the guide motif followed by NNGRRT PAMs. d, Pooled indel values 
for NNGRR(A), (C), (G), or (T) PAM combinations (n=12, 21, 39, and 44 respectively).
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Figure 3. Characterization of genome-wide nuclease activity of SaCas9 and SpCas9
a, Schematic of BLESS processing steps. b, Manhattan plots of genome-wide DSB clusters 
generated by each Cas9 and sgRNA pair, with on-target loci shown above. c, Correlation 
between DSB scores and indel levels for top-scoring DSB clusters. Trendlines, r2, and p-
values are calculated using ordinary least squares. d, Off-target loci from BLESS with 
detectable indels through targeted deep sequencing (n=3) are shown. Heatmaps indicate 
DSB score (blue), motif score from ChIP (purple), or sequence similarity score (green) for 
each locus. Blue triangles indicate peak positions of BLESS signal.
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Figure 4. AAV-delivery of SaCas9 for in vivo genome editing
a, Single-vector AAV system and experimental timeline. b, Indels at Pcsk9 targets in liver 
tissue following injection of AAV at 2E11 total genome copies (n=3 animals). Time course 
of c, serum Pcsk9 and d, total cholesterol in animals (n=3 for all titers and time points, error 
bars show S.E.M.). e, Manhattan plots of BLESS-identified DSB clusters in N2a cells. Inset 
indicates indel levels at top DSB scoring loci. f, Indels in liver tissue (n=3 animals, error 
bars indicate Wilson intervals) at BLESS-identified off-target loci. Heatmap indicates DSB 
scores.
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Figure 5. Liver function tests and toxicity examination in injected animals
a., Histological analysis of the liver at 1-week post-injection by H&E stain. Scale bar = 
10μm. b, Liver function tests in Pcsk9-targeted (both Pcsk9-sg1 and Pcsk9-sg2; 2E11 total 
genome copies, n ≥ 4), TBG::EGFP injected (2E11 total genome copies, n=3), and un-
injected (n=5) animals. Dashed lines show the upper and lower ranges of normal value in 
mice where applicable.
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